iiinova — where your digital self keeps evolving

ICR_DDU_IIT @icrdduiit.bsky.social · 29/09/2026

🧬DDU IIT Team Update! 🧬 We are so thrilled to welcome back Shinee Gunasekara as our new Clinical Research Associate along with Kiara Alakija as our Clinical Research Operations Coordinator. We are pleased to have them as part of the sponsor team and look forward to the insight they will bring us!🙌

000

ICR_DDU_IIT @icrdduiit.bsky.social · 22/09/2026

🧬 A new chapter at DDU IIT! 🧬 Please join us in welcoming Clinical Trial Assistants Theresa Varghese & Aleena Zaman to the sponsor team! We’re also saying a fond farewell to Soyoung Kim & Lossiga Rajahvisvalingam. Thank you for your dedication, and best wishes for your final year at university!💙

000

ICR_DDU_IIT @icrdduiit.bsky.social · 08/08/2025

🚨Now recruiting at the DDU: IDOL, a Phase I/Ib trial for ovarian cancer, testing Idetrexed + Olaparib. Help shape the future of ovarian cancer care. 📍Royal Marsden, Sutton 🔗 ClinicalTrials.gov (NCT06976892) #OvarianCancer #IDOLTrial #DDU #ICR #CancerResearch #TargetedTherapy

clinicaltrials.gov

ClinicalTrials.gov

010

ICR_DDU_IIT @icrdduiit.bsky.social · 23/06/2025

🚨 Now recruiting at the DDU: ASpiRE, a Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC), testing SX-682 + Apalutamide. Help shape the future of prostate cancer care. 📍Royal Marsden, Sutton 🔗ClinicalTrials.gov (NCT07002320) #ProstateCancer #ASpiRETrial #DDU #ICR

020

ICR_DDU_IIT @icrdduiit.bsky.social · 20/05/2025

Happy #InternationalClinicalTrialsDay! 🎉 At DDU-IIT @icr.ac.uk , we’re proud to help turn cutting-edge science into real-world impact. 🔬🌍 To the patients, families & teams behind every trial—your courage fuels the future of medicine. ❤️‍🔥 #ClinicalTrialsDay #ICR #RoyalMarsden #ResearchMatters#ACRP

062

ICR_DDU_IIT @icrdduiit.bsky.social · 12/05/2025

FDA grants accelerated approval for Avmapki™ + Fakzynja™ in KRAS-mutant LGSOC. The decision was supported by Phase 1 FRAME trial led by Prof. Udai Banerji and RAMP 201 led by Prof. Susana Banerjee. Our thanks to all the patients & their families. #VerastemOncology, #ICR, #RoyalMarsden

020

ICR_DDU_IIT @icrdduiit.bsky.social · 02/05/2025

🚀 Trial Opportunity! Phase I POTENT trial is recruiting at 4 UK sites—evaluating tepotinib (MET inhibitor) + pembrolizumab (immunotherapy) in NSCLC. 🔍 We warmly invite clinicians to refer suitable patients! 📄 More info: clinicaltrials.gov/NCT05782361 #LungCancer #ClinicalTrials

clinicaltrials.gov

ClinicalTrials.gov

010

ICR_DDU_IIT @icrdduiit.bsky.social · 25/04/2025

Our Investigator Initiated Trial, POTENT, presented at #ELCC2025 by Dr Anna Minchom combines tepotinib + pembrolizumab to tackle immune resistance in NSCLC. Promising early results prelude to expanding treatment options & improving outcomes for NSCLC patients. #LungCancer #DDUIIT

020